{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:45:43Z","timestamp":1782906343076,"version":"3.54.5"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T00:00:00Z","timestamp":1645920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>CD28\u2010based CD19 chimaeric antigen receptor\u2010modified (CAR\u2010)Tcells were recently FDA\u2010approved for adult acute lymphoblastic leukaemia (ALL). We report long\u2010term outcome of 37 children and young adults treated with autologous CD19 CAR\u2010T cells. The complete remission rate was 86%, of which 71% were polymerase chain reaction (PCR) minimal residual disease (MRD)\u2010negative, 14% were MRD\u2010negative by flow cytometry, and 14% were PCR MRD\u2010positive. 26 patients proceeded to subsequent haematopoietic stem cell transplant (HSCT). 11 patients had a CD19\u2010postive relapse (eight post HSCT and three without) and one had a CD19\u2010negative relapse. All relapse events occurred within two years from cell therapy. With a median follow\u2010up of three years, the median event\u2010free survival (EFS) is 17\u00a0months and the median overall survival (OS) is not reached. The three\u2010year EFS is 41% and OS is 56%. Patients with &gt;5% blasts in the bone marrow prior to lymphodepletion had an inferior EFS. All patients with a PCR MRD\u2010positive result at day 28 had relapsed after CAR\u2010T\u2010cell therapy. A prior HSCT did not significantly affect outcome, but a consolidative transplant after achieving remission improved long\u2010term results. Overall, prelymphodepletion disease burden and molecular MRD negativity following CAR\u2010T cells are predictors of long\u2010term outcome following CD19 CAR\u2010T\u2010cell therapy for ALL.<\/jats:p>","DOI":"10.1111\/bjh.18105","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T02:29:44Z","timestamp":1646015384000},"page":"475-481","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Parameters of long\u2010term response with <scp>CD28<\/scp>\u2010based <scp>CD19 chimaeric antigen receptor\u2010modified<\/scp> T cells in children and young adults with <scp>B\u2010acute lymphoblastic leukaemia<\/scp>"],"prefix":"10.1111","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-8942","authenticated-orcid":false,"given":"Elad","family":"Jacoby","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology and Oncology The Edmond and Lily Safra Children's Hospital, Sheba Medical Center  Tel Hashomer Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Bielorai","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology The Edmond and Lily Safra Children's Hospital, Sheba Medical Center  Tel Hashomer Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna","family":"Hutt","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology The Edmond and Lily Safra Children's Hospital, Sheba Medical Center  Tel Hashomer Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Itzhaki","sequence":"additional","affiliation":[{"name":"Ella Institute of Immuno\u2010Oncology Sheba Medical Center  Tel Hashomer Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etai","family":"Adam","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology The Edmond and Lily Safra Children's Hospital, Sheba Medical Center  Tel Hashomer Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bar","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology The Edmond and Lily Safra Children's Hospital, Sheba Medical Center  Tel Hashomer Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal J.","family":"Besser","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"},{"name":"Ella Institute of Immuno\u2010Oncology Sheba Medical Center  Tel Hashomer Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Toren","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology The Edmond and Lily Safra Children's Hospital, Sheba Medical Center  Tel Hashomer Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12774"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010021\u201001281\u20107"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201002\u2010769208"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)61403\u20103"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010019\u20100549\u20105"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30864\u20107"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00375\u20102"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010019\u20101054\u20101"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201019\u20100945"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)01222\u20108"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25274"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102019\u2010000148"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02262"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001641"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012392"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201011\u2010883710"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102021\u2010003644"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.11.019"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01405"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.2520"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.bcd\u201021\u20100095"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010019\u20100604\u20103"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.003"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125423"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03237"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18105","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18105","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:43:07Z","timestamp":1692841387000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,27]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/bjh.18105"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18105","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,27]]},"assertion":[{"value":"2022-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}